Investor Presentaiton

Compounding tailwinds are driving new royalty opportunities Drug development complexity and industry collaborations Increasing industry participants with capital needs Increasing drug approvals and applications New modalities (cell/gene therapy, etc.) Biologic understanding of disease 1 ROYALTY PHARMA 4 3 2 5 New royalty opportunities 108

View entire presentation